Huntington’s Disease Gene Therapy AMT-130 Gets FDA Priority Review: The Science, the Evidence and What Comes Next

The U.S. Food and Drug Administration has accepted uniQure’s application for AMT-130, an investigational Huntington’s disease gene therapy, and granted it Priority Review. The agency set a target action date of May 1, 2027, and said it tentatively plans to take the application to an outside advisory committee. If approved, AMT-130 (generic name ifezuntirgene inilparvovec) would be the first therapy designed to slow the underlying course of Huntington’s disease rather than only ease its symptoms. The filing rests on a small, externally controlled dataset that the FDA itself questioned earlier this year, so the review is likely to be closely watched.

What happened: Huntington’s disease gene therapy enters FDA review

Verified facts

• On November 2, 2026, uniQure N.V. (Nasdaq: QURE) announced that the FDA accepted its Biologics License Application (BLA) for AMT-130. The company submitted it under the Accelerated Approval pathway.
• The FDA granted Priority Review. The PDUFA target action date is May 1, 2027.
• uniQure says the FDA’s acceptance letter states the agency is “tentatively planning” to discuss the application at an Advisory Committee meeting. No date has been set.
• AMT-130 already holds Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.
• uniQure reported the acceptance again in its third-quarter 2026 results on November 4, 2026. The company also said the UK’s MHRA validated its marketing application in the third quarter.

The science in plain language

Huntington’s disease is an inherited brain disorder. It is caused by an expanded stretch of DNA in the HTT gene, which makes a toxic form of the huntingtin protein. Over years, the disease damages nerve cells, especially in a deep brain region called the striatum. People gradually lose control of movement, thinking and mood. Until now, available medicines have treated symptoms only.

AMT-130 takes a different approach:

• Delivery: A neurosurgeon uses MRI guidance to infuse the therapy directly into the striatum in a one-time procedure.
• Mechanism: The therapy uses a harmless viral shell (an AAV5 vector) to deliver genetic instructions. Brain cells then make a small RNA that lowers production of the huntingtin protein.
• Goal: Reducing the harmful protein should slow the disease’s progression.

The evidence so far

The application relies on data from Phase I/II studies (NCT04120493 and NCT05243017). These results were compared against a propensity score–matched external control group drawn from the Enroll-HD natural history database. That means the comparison patients were people tracked in a separate observational registry. They were not randomized to placebo within the trial.

Company-reported results (not yet peer-reviewed)

Source: uniQure Q3 2026 release. “Nominal” p-values are not adjusted for multiple comparisons.

• The company also reported that patients on the high dose declined less than those on the low dose, which it describes as consistent with a dose-dependent effect.
• Levels of neurofilament light chain (NfL), a blood and spinal-fluid marker of nerve damage, “remained near baseline at 48 months,” according to uniQure.
• Safety: uniQure describes AMT-130 as “generally well tolerated with a manageable safety profile” across 51 treated patients.

Why the evidence is debated

The dataset is small, and the comparison group was not treated at the same time as the study patients. In a March 2, 2026 regulatory update, uniQure disclosed that the FDA, at a January 30, 2026 meeting, said it “cannot agree” that the Phase I/II data compared to an external control were enough to provide the primary evidence of effectiveness. The agency recommended a randomized, sham surgery–controlled study at that time. The company has not explained publicly in detail how the two sides came to accept the current filing. Independent coverage, including Medical Daily, notes that the full dataset has not yet appeared in a peer-reviewed journal.

Company statements

uniQure CEO Matt Kapusta said the acceptance “marks an important milestone for the Huntington’s disease community.” He also said the confirmatory trial “remains a key priority.”

uniQure says it has aligned with the FDA on the main features of that confirmatory study:

• About 200 patients, randomized 2:1 to AMT-130 or standard of care
• Total Functional Capacity at 36 months as the primary endpoint
• U.S. screening expected to begin by the end of 2026

The company reported $768.4 million in cash, cash equivalents and investment securities as of September 30, 2026. It says that is expected to fund operations into 2030, and it is building commercial teams ahead of a possible launch. No price has been announced.

Who could benefit

As reported by Medical Daily, the Huntington’s Disease Society of America estimates that about 41,000 Americans have symptoms of the disease and more than 200,000 are at risk of inheriting it. The trials enrolled people with early-stage disease. The label, if the therapy is approved, will determine exactly who is eligible.

What comes next

• Advisory committee: A date has not been set. Outside experts would likely weigh how reliable the external-control comparison is.
• May 1, 2027: FDA target action date.
• Late 2026: Expected start of screening for the randomized confirmatory trial. Under Accelerated Approval, the FDA usually requires confirmatory evidence of clinical benefit.
• Other Huntington’s programs: In late October, Alnylam (Nasdaq: ALNY) reported early Phase 1b data for brezosiran, an RNAi drug that also aims to lower huntingtin. That program is at a much earlier stage.

Analysis: what to watch

This section is Vanderbiltreport editorial analysis, not a forecast. The key question for regulators is whether a benefit measured against a registry comparison group is convincing enough to support accelerated approval for a one-time, surgically delivered gene therapy. The advisory committee discussion, the full peer-reviewed data and the progress of the randomized trial will shape that judgment.

Related Biotechnology coverage on Vanderbiltreport.com

• FDA Approves Hibsago: A New Chronic Hepatitis B Treatment Aims for a “Functional Cure”
• FDA Approves Emcitate, the First MCT8 Deficiency Treatment
• FDA Panel Backs GRAIL’s Galleri Multi-Cancer Early Detection Test
• Petosemtamab Phase 3 Results: Genmab Head and Neck Cancer Drug

Sources

• uniQure press release, Nov. 2, 2026 (GlobeNewswire)
• uniQure Q3 2026 results, Nov. 4, 2026 (GlobeNewswire)
• uniQure regulatory update, Mar. 2, 2026
• Medical Daily, Nov. 3, 2026
• PharmaShots, Nov. 3, 2026

Publisher Disclaimer: Vanderbiltreport.com publishes news and information for general informational and educational purposes. Information is compiled from sources believed to be reliable, but Vanderbiltreport.com does not guarantee the accuracy, completeness, or timeliness of all information presented. Readers should independently verify information and conduct their own research before making financial, investment, business, or other decisions.